Suture loop to aid in ganciclovir implant removal
- PMID: 10496404
- DOI: 10.1001/archopht.117.9.1250
Suture loop to aid in ganciclovir implant removal
Abstract
Background: The ganciclovir implant (Vitrasert; Bausch & Lomb Inc, Claremont, Calif) has been a useful device in the management of cytomegalovirus retinitis. Seven months after placement, implant exchange is often considered. However, removal may be difficult and may result in vitreous hemorrhage or intraocular dislocation.
Objective: To describe a suture loop attached to the implant strut and left in the sub-Tenon space to aid in implant removal.
Methods: Twenty-five eyes of 17 patients received a ganciclovir implant with an 8-0 nylon suture loop left beneath the Tenon capsule and underwent at least 6 months of follow-up. Two of these eyes subsequently had a similarly modified ganciclovir implant placed at a separate site (inferonasally) with at least 6 additional months of follow-up. Six eyes of 3 patients had the implant removed as part of an exchange and underwent at least 4 months of follow-up.
Results: In the 25 eyes, there were no cases of endophthalmitis, wound leak, suture exposure, or other complications. At implant removal in the 6 eyes previously mentioned, the loop was used for traction on the implant and aided in localization of the implant strut. In these 6 eyes, there were no cases of retinal or choroidal detachment, visually significant vitreous hemorrhage, implant dislocation, or other complications.
Conclusion: A sub-Tenon capsule suture loop is well tolerated and can assist in ganciclovir implant removal.
Similar articles
-
Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis.Am J Ophthalmol. 1999 Mar;127(3):288-93. doi: 10.1016/s0002-9394(98)00443-7. Am J Ophthalmol. 1999. PMID: 10088738
-
Ganciclovir implant exchange. Timing, surgical procedure, and complications.Arch Ophthalmol. 1997 Nov;115(11):1389-94. doi: 10.1001/archopht.1997.01100160559005. Arch Ophthalmol. 1997. PMID: 9366668 Clinical Trial.
-
A single-suture technique for placement of the ganciclovir implant.Arch Ophthalmol. 2000 Apr;118(4):584-5. doi: 10.1001/archopht.118.4.584. Arch Ophthalmol. 2000. PMID: 10766152
-
Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis.Arch Ophthalmol. 1996 Jul;114(7):815-20. doi: 10.1001/archopht.1996.01100140029003. Arch Ophthalmol. 1996. PMID: 8660164
-
Ganciclovir implant in the treatment of cytomegalovirus retinitis.Expert Rev Med Devices. 2005 Jul;2(4):421-7. doi: 10.1586/17434440.2.4.421. Expert Rev Med Devices. 2005. PMID: 16293081 Review.
Cited by
-
Liposomes and nanotechnology in drug development: focus on ocular targets.Int J Nanomedicine. 2013;8:495-503. doi: 10.2147/IJN.S30725. Epub 2013 Feb 14. Int J Nanomedicine. 2013. PMID: 23439842 Free PMC article. Review.
-
Nanocarriers of nanotechnology in retinal diseases.Saudi J Ophthalmol. 2014 Oct;28(4):304-9. doi: 10.1016/j.sjopt.2014.02.009. Epub 2014 Mar 5. Saudi J Ophthalmol. 2014. PMID: 25473348 Free PMC article. Review.
-
Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.J Ocul Pharmacol Ther. 2013 Jun;29(5):493-500. doi: 10.1089/jop.2012.0205. Epub 2013 Feb 28. J Ocul Pharmacol Ther. 2013. PMID: 23448595 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources